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Background. -e influence of HLA class I and II loci on the susceptibility to melanoma remains an area of intense debate. -is
study aimed to examine whether the HLA system was related to melanoma susceptibility and prognosis in a southern Spanish
population. Methods. In this study, HLA class I and class II genotyping were performed using polymerase chain reaction se-
quence-specific oligonucleotides (PCR-SSO) in 237 Spanish melanoma patients and 636 ethnically matched controls. Data were
analyzed according to the clinical characteristics of the defined subgroups. Results. Compared to the control group, DRB1∗ 16:01
(4% vs. 1.3%, p � 0.001, Pc� 0.035, OR� 3.28) and DQB1∗ 05:02 (4.9% vs. 2%, p � 0.001, Pc� 0.017, OR� 2.54) were positivity
associated with the susceptibility to melanoma. Both DRB1∗ 16:01 (5.4% vs. 1.3%, p � 0.001, Pc� 0.035, OR� 4.46) and
DQB1∗ 05:02 (6.5% vs. 2%, p � 0.001, Pc� 0.017, OR� 3.44) also showed a positive correlation with Breslow thickness >1.5mm,
most notably at an early age of diagnosis (≤58 years), DRB1∗ 16:01 (4.2% vs. 1.3%, p � 0.001, Pc� 0.035, OR� 3.41) and
DQB1∗ 05:02 (5.4% vs. 2%, p � 0.002, Pc� 0.034, OR� 2.86). Conclusion. -ese findings established HLA-DRB1∗ 16:01 and
HLA-DQB1∗ 05:02 loci as melanoma risk factors in the southern Spanish population.
1. Introduction
Malignant melanoma is characterized by a variable clinical
outcome due to the complex interactions of human leu-
kocyte antigens (HLAs), antigen-specific cytolytic T cells
(CTLs), and natural killer (NK) cells [1–3]. During immune
surveillance, HLA class I molecules participate in tumor cell
recognition for CD8+ T-cell-mediated clearance [4, 5],
whilst HLA class II molecules stimulate CD4+ T cells to
combat melanoma progression [6]. It is, therefore,
speculated that the susceptibility to melanoma is closely
associated with specific HLA genes [7].
Studies have reported the association betweenmelanoma
and HLA genes with variable outcomes. Ichimiya et al.
observed an increase in the HLA-B13 antigen and a decrease
in the frequency of the HLA-B61 antigen in Japanese
melanoma patients compared to healthy controls [8].
Schachter et al. reported an increase in the frequency of
HLA-A24, -A26, and -B38 antigens in Jewish melanoma
patients compared with control cases [9]. Luongo et al.
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described the association of HLA-A∗ 01 with less aggressive
disease, which negatively associated with HLA-B∗ 13 and
HLA-B∗ 44 in Italian melanoma patients [10]. In contrast,
Campillo et al. observed no association with any HLA class I
alleles in southeastern Spanish patients and described an
association for patients homozygous for group C2 (lysine at
position 80) of HLA-C recognized by the killer immuno-
globulin-like receptors (KIRs) with metastatic progression.
A negative association between group C1 (asparagine at
position 80) and the susceptibility to melanoma progression
and metastasis have also been reported [11].
Conflicting results have also been reported in studies
investigating the role of HLA class II genes in melanoma
susceptibility. Barger et al. described the first positive as-
sociation between the HLA-DR4 allele and melanoma
susceptibility in the Caucasian American population of
Alabama, in which the HLA-DR3 allele favorably influenced
prognosis [12]. HLA-DQB1∗ 03:01 was more frequent in
melanoma patients than in a control series of 45 patients
(Lee et al., 1994) and represented a risk factor for local
recurrence and the generation of regional and distant me-
tastases in 259 American patients (Lee et al., 1996) [13, 14].
An increase in the frequency of HLA-DQB1∗ 03:01 was
observed in Italian melanoma patients but without statistical
significance [15]. In the English population, similar results
were obtained for DQB1∗ 03:01 in terms of the risk of
melanoma, but the most frequent allele in patients was HLA-
DQB1∗ 03:03 as opposed to HLA-DQB1∗ 03:01 [16].
Conversely, Lulli et al. observed a decrease in the frequency
of HLA-DQB1∗ 03 and all haplotypes that included three
alleles within the family DQB1∗ 03:01, DQB1∗ 03:02, and
DQB1∗ 03:03, although this study included only 53 mela-
noma patients [17]. Luongo et al. also observed no associ-
ation between HLA class II genes and the susceptibility to
melanoma [10]. In two Spanish studies performed in
Valencia (Nagore et al. and Planelles et al.) and Murcia
(Campillo et al.) and in a cohort of Japanese patients, no
association was observed between the HLA-DRB1 andHLA-
DQB1 alleles and human malignant melanoma [11, 18, 19].
In this study, we expanded the number of patients
(n� 237) and control subjects (n� 636) to define the re-
lationship more accurately between melanoma susceptibility
and the frequency of HLA genes.
2. Materials and Methods
2.1. Patients/Controls. Blood samples were obtained from
237 patients diagnosed with melanoma. Tumor staging was
performed from biopsy samples according to the criteria of
the American Joint Committee on Cancer TNM staging
system (AJCC 2018) at the Dermatology Service of Virgen de
las Nieves University Hospital of Granada, Spain. Exclusion
criteria were as follows: cardiac disease, autoimmune dis-
ease, and diabetes mellitus. Control subjects included 637
age- and gender-matched healthy donors obtained from the
blood bank of Granada. All healthy donors had no in-
dication of immune-related disease. Blood samples were
collected from 2016 to 2019. Patient blood samples were
obtained prior to primary melanoma excision. All subjects
provided written informed consent. -e study protocol was
approved by the hospital institutional review board and
ethical committee. -e clinicopathological characteristics of
the patients are summarized in Table 1.
2.2. DNA Extraction and Determination of HLAClass I and II
Genotypes. Genomic DNA was extracted from peripheral
venous blood leukocytes using commercial QIAamp DNA
Blood Maxi Kits (QIAGEN, Hilden, Germany) according to
themanufacturer’s instructions. High-resolution genotyping of
HLA class I (A, B, and C) and class II (DRB1 and DQB1) loci
typing was performed using the LABType sequence-specific
oligonucleotide typing test (One Lambda, Canoga Park, CA,
USA). Target DNA was amplified by PCR using HLA locus-
specific primers, followed by hybridization with allele-specific
oligodeoxynucleotides coupled with fluorescent phycoery-
thrin-labeled microspheres. Allele genotyping was determined
based on the reaction pattern of the microspheres using the
LABScan 100 system (Luminex xMAP, Austin, TX, USA).
HLA alleles were assigned using HLA Fusion software (One
Lambda). HLA typing was presented as four digits, taking into
account the common and well-defined alleles (CWD).
2.3. Statistical Analysis. SPSS.20 (SPSS Inc., Chicago, IL,
USA) was used for all data analyses. Differences in allele
frequencies between melanoma patients and the control
groups were evaluated using the chi-square method (χ2,
Mantel–Haenszel) using 3× 2 or 2× 2 contingency tables.
Fisher’s exact test was applied for predicted values ≤5. -e
strength of an association was calculated using the odds ratio
(OR) according to the Woolf method with Haldane mod-
ifications for 95% confidence intervals (CIs). p values ≤0.05
were considered statistically significant. Pc (i.e., corrected p)
was the p value of the Bonferroni correction. Bonferroni
correction was performed through the multiplication of all
alleles assessed within each locus.
3. Results
3.1. HLA Frequency in Melanoma Patients. -e frequencies
of HLA-A, -B, and -C alleles in 237 melanoma patients were
compared with 637 normal control subjects of the same
ethnic origin (Table 2). Within the patient cohort, 30 alleles
for HLA-A, 49 alleles for HLA-B, and 25 alleles for HLA-C
were detected. No significant differences in the frequency of
HLA-A, -B, and -C alleles were observed between groups,
although some were of higher number in melanoma patients
compared with healthy controls (HLA-A∗ 02:05: 3% vs.
1.1%, p � 0.006, Pc� 0.18, and HLA-B∗ 35:03: 3.6% vs.
1.5%, p � 0.006, Pc� 0.29).
For HLA class II, 35 HLA-DRB1 and 17 HLA-DQB1
alleles were identified. Only the frequencies of DRB1∗ 16:01
(4% vs. 1.3%, p � 0.001, Pc� 0.035, OR� 3.28) and
DQB1∗ 05:02 (4.9% vs. 2%, p � 0.001, Pc� 0.017,
OR� 2.54) significantly increased in melanoma patients.
Previous studies reported that HLA-DQB1∗ 03:01,
-DQB1∗ 03:02, -DQB1∗ 03:03, and -DQB1∗ 05:01 alleles
were associated with melanoma, but no association of these
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alleles between melanoma patients and healthy controls was
observed in our cohort (DQB1∗ 03:01: 18.6% vs. 17.9%,
p � 0.757; DQB1∗ 03:02: 5.9% vs. 9.2%, p � 0.027,
Pc� 0.459; DQB1∗ 03:03: 2.5% vs. 3.4%, p � 0.366;
DQB1∗ 05:01: 13.1% vs. 14.4%, p � 0.484, Table 3).
3.2. HLA Frequency and Melanoma Prognosis. Breslow
thickness is a strong predictor of patient survival as it defines
the depth of tumor invasion from the granular stratum to the
deepest penetrating melanoma cells. In this study, patient and
control groups were defined as having a Breslow thickness of
≤1.5mm (low risk, n� 144) or >1.5mm (intermediate or high
risk, n� 93), as described by Planelles et al. in Spanish
melanoma patients [19]. -ese analyses revealed that
DRB1∗ 16:01 (5.4% vs. 1.3%, p � 0.001, Pc� 0.035, OR�
4.46) and DQB1∗ 05:02 (6.5% vs. 2%, p � 0.001, Pc� 0.017,
OR� 3.44) were of significantly higher frequency in the
subgroup with Breslow thickness >1.5mm compared with
healthy controls. No significant differences were observed
between HLA-A, -B, and -C alleles in the subgroup with
Breslow thickness >1.5mm. Neither HLA-A, -B, and -C nor
HLA-DRB1 and -DQB1 showed significant differences in the
subgroup with a Breslow thickness of ≤1.5mm.
To explore the correlation between the HLA allele fre-
quency and the age of diagnosis, Planelles et al. used a cutoff
of 30 years [19]. -is grouping standard was not applicable
to our patient cohort given their older age (only 14 cases
aged ≤30 years; median age: 58 years). Melanoma patients
were therefore divided into two subgroups according to their
age of diagnosis: ≤58 years (n� 119) or >58 years (n� 118).
DRB1∗ 16:01 (4.2% vs. 1.3%, p � 0.001, Pc� 0.035,
OR� 3.41) and DQB1∗ 05:02 (5.4% vs. 2%, p � 0.002,
Pc� 0.034, OR� 2.86) (Table 4) were of a significantly higher
frequency in the subgroup with the age of diagnosis ≤58
years compared to healthy controls. No significant differ-
ences in HLA-A, -B, and -C alleles were observed in subjects
aged >55 years.
-ere was no significant difference in frequency between
patients with a Breslow thickness of ≤1.5mm and >1.5mm
nor between those aged ≤58 years and >58 years.
To study the differences in the frequency of HLA alleles
according to the melanoma type, 154 cases of superficial
spreading melanoma (SSM), 54 cases of nodular melanoma
(NM), 19 cases of lentigo maligna melanoma (LMM), and 10
cases of acral lentiginous melanoma (ALM) were compared.
Following these analyses, no significant differences were
observed between melanoma and control groups. -e fre-
quency of HLA class I and HLA class II antigens also did not
significantly differ between the sentinel lymph node me-
tastasis and ulceration cases.
3.3. HLA Homozygosity in Melanoma Patients. To further
explore the correlation between HLA alleles and melanoma,
we compared the homozygosity frequency of HLA-A, -B,
and -C and HLA-DRB1 and -DQB1 between melanoma
patients and healthy controls. Homozygosity frequency of
different HLA alleles was also performed according to the
clinicopathological features of each patient subgroup. No
significant differences following these analyses were
observed.
4. Discussion
In this study, we performed a comprehensive analysis of
polymorphisms of HLA class I and class II alleles in southern
Spanish patients with melanoma. We found that HLA-
DRB1∗ 16:01 and HLA-DQB1∗ 05:02 were of a higher
frequency in melanoma patients compared with healthy
controls (Table 3), suggesting that these two loci may be
related to the susceptibility of melanoma. Interestingly,
when we investigated the association between HLA allele
frequency and clinical and histological parameters, the
frequency of both loci was found to be significantly increased
in patients with an intermediate or high risk of Breslow
thickness (Breslow thickness >1.5mm) (Table 4). Breslow
thickness is an important predictor of patient survival and
a key parameter of the AJCC TNM classification for primary
melanoma patients. A higher Breslow thickness indicates
lower mortality and a more advanced tumor stage; for ex-
ample, tumors ≤1.0mm are designated as low risk with 10-
year survival rates of 92%; tumors between 1.01 and 2.0mm
have 10-year survival rates of 80%; tumors measuring 2.01 to
4.0mm have 10-year survival rates of 63%; tumors ≧4mm
have 10-year survival rates of 50% [20, 21]. In addition, age is
also an important factor that affects the prognosis of mel-
anoma. Many studies have shown that elderly patients with
melanoma have a worse prognosis and that melanoma
Table 1: Clinical characteristics.








≤58 years 119 50.2
>58 years 118 49.8
Histological type
Superficial spreading
melanoma (SSM) 154 64.9
Nodular
melanoma (NM) 54 22.8
Lentigo maligna
melanoma (LMM) 19 8
Acral lentiginous







Sentinel lymph node biopsy
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patients over the age of 60 are a high-risk group [22, 23]. In
this study, HLA-DRB1∗ 16:01 and HLA-DQB1∗ 05:02 were
significantly increased in the subgroup of patients diagnosed
at an early age (age of diagnosis of ≤58 years). -is indicated
that HLA-DRB1∗ 16:01 and HLA-DQB1∗ 05:02 may be
related to the susceptibility of melanoma and play an im-
portant role in melanoma progression.
It should be noted that, within the Spanish population,
HLA-DRB1∗ 16:01 and HLA-DQB1∗ 05:02 were not the
most frequent loci. HLA-DRB1∗ 16:01 had an allele
























A∗01:01 127 (0.1) 42 (0.089) B∗07:02 117 (0.092) 31 (0.065) C∗01:02 41 (0.032) 13 (0.027)
A∗01:02 2 (0.002) 0 (0) B∗07:05 2 (0.002) 0 (0) C∗02:02 63 (0.05) 36 (0.076)
A∗01:03 1 (0.001) 0 (0) B∗07:06 5 (0.004) 0 (0) C∗02:10 1 (0.001) 0 (0)
A∗02:01 312 (0.245) 116 (0.245) B∗08:01 64 (0.05) 26 (0.055) C∗03:02 5 (0.004) 0 (0)
A∗02:02 5 (0.004) 2 (0.004) B∗13:02 21 (0.017) 10 (0.021) C∗03:03 30 (0.024) 12 (0.025)
A∗02:05 14 (0.011) 14 (0.03) B∗14:01 21 (0.017) 7 (0.015) C∗03:04 22 (0.017) 10 (0.021)
A∗02:06 2(0.002) 1 (0.002) B∗14:02 48 (0.038) 25 (0.053) C∗04:01 184 (0.145) 57 (0.12)
A∗03:01 121 (0.095) 40 (0.084) B∗15:01 39 (0.031) 18 (0.038) C∗05:01 143 (0.112) 51 (0.108)
A∗03:02 7(0.006) 2 (0.004) B∗15:03 8 (0.006) 1 (0.002) C∗06:02 103 (0.081) 47 (0.099)
A∗11:01 94 (0.074) 36 (0.076) B∗15:16 2 (0.002) 0 (0) C∗07:01 159 (0.125) 65 (0.137)
A∗23:01 41 (0.032) 12 (0.025) B∗15:17 9 (0.007) 1 (0.002) C∗07:02 131 (0.103) 30 (0.063)
A∗24:02 135 (0.106) 38 (0.08) B∗15:18 8 (0.006) 1 (0.002) C∗07:04 14 (0.011) 10 (0.021)
A∗24:03 3 (0.002) 1 (0.002) B∗18:01 131 (0.103) 42 (0.089) C∗08:01 1 (0.001) 0 (0)
A∗25:01 22 (0.017) 10 (0.021) B∗27:02 5 (0.004) 4 (0.008) C∗08:02 67 (0.053) 31 (0.065)
A∗26:01 45 (0.035) 23 (0.049) B∗27:03 3 (0.002) 0 (0) C∗08:03 0 (0) 1 (0.002)
A∗29:01 7 (0.006) 3 (0.006) B∗27:05 33 (0.026) 10 (0.021) C∗12:02 24 (0.019) 6 (0.013)
A∗29:02 94 (0.074) 32 (0.068) B∗27:07 2 (0.002) 2 (0.004) C∗12:03 77 (0.061) 33 (0.07)
A∗30:01 32 (0.025) 10 (0.021) B∗35:01 86 (0.068) 18 (0.038) C∗14:02 19 (0.015) 6 (0.013)
A∗30:02 42 (0.033) 19 (0.04) B∗35:02 15 (0.012) 6 (0.013) C∗15:02 47 (0.037) 11 (0.023)
A∗30:04 0 (0) 1 (0.002) B∗35:03 19 (0.015) 17 (0.036) C∗15:04 1 (0.001) 0 (0)
A∗31:01 25 (0.02) 12 (0.025) B∗35:08 11 (0.009) 4 (0.008) C∗15:05 7 (0.006) 2 (0.004)
A∗32:01 43 (0.034) 18 (0.038) B∗37:01 14 (0.011) 13 (0.027) C∗16:01 96 (0.075) 32 (0.068)
A∗33:01 29 (0.023) 15 (0.032) B∗38:01 32 (0.025) 16 (0.034) C∗16:02 19 (0.015) 8 (0.017)
A∗34:02 6 (0.005) 0 (0) B∗39:01 14 (0.011) 6 (0.013) C∗16:04 0 (0) 1 (0.002)
A∗66:01 6 (0.005) 7 (0.015) B∗39:06 4 (0.003) 3 (0.006) C∗17:01 18 (0.014) 8(0.017)
A∗68:01 35 (0.028) 9 (0.019) B∗40:01 21 (0.017) 10 (0.021)
A∗68:02 9 (0.007) 8 (0.017) B∗40:02 14 (0.011) 5 (0.011)
A∗69:01 4 (0.003) 2 (0.004) B∗40:06 3 (0.002) 1 (0.002)
A∗74:01 2 (0.002) 0 (0) B∗41:01 12 (0.009) 9 (0.019)
A∗80:01 7 (0.006) 0 (0) B∗41:02 3 (0.002) 2 (0.004)
B∗42:01 0 (0) 1 (0.002)
B∗44:01 2 (0.002) 0 (0)
B∗44:02 70 (0.055) 31 (0.065)
B∗44:03 123 (0.097) 40 (0.084)
B∗44:05 1 (0.001) 1 (0.002)
B∗45:01 20 (0.016) 4 (0.008)
B∗47:01 3 (0.002) 0 (0)
B∗48:01 1 (0.001) 1 (0.002)
B∗49:01 33 (0.026) 19 (0.04)
B∗50:01 36 (0.028) 16 (0.034)
B∗50:02 4 (0.003) 1 (0.002)
B∗51:01 112 (0.088) 42 (0.089)
B∗51:08 5 (0.004) 3 (0.006)
B∗52:01 20 (0.016) 4 (0.008)
B∗53:01 15 (0.01) 5 (0.011)
B∗55:01 9 (0.007) 3 (0.006)
B∗56:01 3 (0.002) 1 (0.002)
B∗57:01 29 (0.023) 8 (0.017)
B∗58:01 16 (0.013) 2 (0.004)
AF: allele frequency; n: number of observed alleles.
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frequency of 1.3% in healthy subjects compared with the 2%
frequency observed for HLA-DQB1∗ 05:02. -e low fre-
quency of these two loci may explain their absence in
previous studies performed in the Spanish population.
Studies performed by Nagore et al. included 82 patients and
367 healthy controls, while Planelles et al. compared HLA
frequency in 117melanoma patients and 301 healthy donors.
Campillo et al. performed their analyses in 174 melanoma
patients and 227 ethnically matched controls [11, 18, 19]. In
this study, the sample size was expanded to 237 melanoma
patients and 637 healthy controls.
As both HLA-DRB1∗ 16:01 and HLA-DQB1∗ 05:02 loci
have been reported as haplotypes in the Spanish population
[24–26], it was not possible to identify which allele was
Table 3: Most frequent HLA class II alleles with the patient cohort.








DRB1∗01:01 103 (0.081) 36 (0.076) DQB1∗02:01 149 (0.117) 58 (0.122)
DRB1∗01:02 41 (0.032) 14 (0.03) DQB1∗02:02 176 (0.138) 76 (0.16)
DRB1∗01:03 12 (0.009) 4 (0.008) DQB1∗03:01 228 (0.179) 88 (0.186)
DRB1∗03:01 148 (0.116) 57 (0.12) DQB1∗03:02 117 (0.092) 28 (0.059)
DRB1∗04:01 36 (0.028) 16 (0.034) DQB1∗03:03 43 (0.034) 12 (0.025)
DRB1∗04:02 24 (0.019) 4 (0.008) DQB1∗03:04 3 (0.002) 1 (0.002)
DRB1∗04:03 37 (0.029) 2 (0.004) DQB1∗03:05 4 (0.003) 1 (0.002)
DRB1∗04:04 32 (0.025) 15 (0.032) DQB1∗03:19 1 (0.001) 0 (0)
DRB1∗04:05 15 (0.012) 7 (0.015) DQB1∗04:02 37 (0.029) 10 (0.021)
DRB1∗04:06 2 (0.002) 2 (0.004) DQB1∗05:01 183 (0.144) 62 (0.131)
DRB1∗04:07 20 (0.016) 1 (0.002) DQB1∗05:02 25 (0.02) 23 (0.049)b
DRB1∗04:08 0 (0) 2 (0.004) DQB1∗05:03 36 (0.028) 9 (0.019)
DRB1∗07:01 210 (0.165) 80 (0.169) DQB1∗06:01 14 (0.011) 9 (0.019)
DRB1∗08:01 29 (0.023) 10 (0.021) DQB1∗06:02 116 (0.091) 41 (0.086)
DRB1∗08:02 3 (0.002) 1 (0.002) DQB1∗06:03 92 (0.072) 33 (0.07)
DRB1∗08:03 2 (0.002) 0 (0) DQB1∗06:04 36 (0.028) 18 (0.038)
DRB1∗08:04 2 (0.002) 0 (0) DQB1∗06:09 12 (0.009) 4 (0.008)
DRB1∗08:06 3 (0.002) 0 (0)
DRB1∗09:01 8 (0.006) 5 (0.011)
DRB1∗10:01 25 (0.02) 8 (0.017)
DRB1∗11:01 84 (0.066) 28 (0.059)
DRB1∗11:02 16 (0.013) 5 (0.011)
DRB1∗11:03 10 (0.008) 1 (0.002)
DRB1∗11:04 39 (0.031) 22 (0.046)
DRB1∗12:01 13 (0.01) 7 (0.015)
DRB1∗13:01 94 (0.074) 34 (0.072)
DRB1∗13:02 49 (0.039) 22 (0.046)
DRB1∗13:03 21 (0.017) 6 (0.013)
DRB1∗13:05 3 (0.002) 2 (0.004)
DRB1∗14:01 32 (0.025) 9 (0.019)
DRB1∗14:04 5 (0.004) 1 (0.002)
DRB1∗15:01 121 (0.095) 44 (0.093)
DRB1∗ 15:02 16 (0.013) 8 (0.017)
DRB1∗15:03 1 (0.001) 0 (0)
DRB1∗16:01 16 (0.013) 19 (0.04)a
AF: allele frequency; n: number of observed alleles. aControl vs. melanoma patients: p � 0.001, Pc� 0.035, and OR� 3.28. bControl vs. melanoma patients:
p � 0.001, Pc� 0.017, and OR� 2.54.
Table 4: Frequency of HLA-associated alleles in melanoma patients grouped according to clinical features.
DRB1∗ 16:01 DQB1∗ 05:02
% p Pc OR % p Pc OR
Control 16 (0.013) 25 (0.02)
Breslow thickness
≤1.5mm 9 (0.031) 0.023 Not significant 11 (0.038) 0.058 Not significant
>1.5mm 10 (0.054) 0.001 0.035 4.46 12 (0.065) 0.001 0.017 3.44
Age at diagnosis
≤58 years 10 (0.042) 0.001 0.035 3.41 13 (0.054) 0.002 0.034 2.86
>58 years 9 (0.038) 0.004 Not significant 10 (0.043) 0.031 Not significant
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responsible for the association or whether coexpression of
both was necessary. -ere are two possible hypotheses for the
association of the HLA-DRB1∗ 16:01-DQB1∗ 05:02 haplo-
type with the susceptibility tomelanoma and a higher Breslow
thickness of the tumor: (1) this haplotype induces the dif-
ferentiation of regulatory T cells that can inhibit the cellular
response to melanoma; (2) this haplotype deactivates CD4+
-1 lymphocytes that recognize peptides generated from
melanoma antigens, thereby preventing their association with
antitumor CD8+ lymphocytes. It has been shown that the
DQB5 molecule (including the DQB1∗ 05:02 variant) pres-
ents Melan-A/MART melanoma antigen peptides to CD4+
lymphocytes with cytotoxic capacity in vitro. -e HLA-
DRB1∗ 16:01 molecule is therefore responsible for the im-
munosuppressive effects observed in melanoma patients [27].
Previous studies reported that HLA-DQB1∗ 03:01,
-DQB1∗ 03:02, -DQB1∗ 03:03, and -DQB1∗ 05:01 alleles
are associated with melanoma [10, 13, 15, 16]. In this study,
no significant frequency of these loci was observed, con-
sistent with previous studies performed in the Spanish
population [11, 18, 19]. -ese discrepancies may be due to
ethnic differences, with previous analyses performed in
American, Italian, and British populations.
We found that specific HLA class I alleles were of
a higher frequency in melanoma patients compared to
healthy controls. -ese differences were however non-
significant following correction for multiple comparisons
due to a large number of each locus. Examples include HLA-
A∗ 02:05 (3% vs. 1.1%, p � 0.006, Pc� 0.18) and HLA-
B∗ 35:03 (3.6% vs. 1.5%, p � 0.006, Pc� 0.296).-ese results
are consistent with previous studies in the Spanish pop-
ulation which concluded that melanoma susceptibility is not
influenced by HLA-A, -B, and -C [11].
Regarding the homozygosity frequency of HLA class I and
class II, no significant differences were observed between
melanoma patients and controls or upon subgroup compari-
sons according to clinicopathological characteristics. Planelles
et al. reported an increased homozygosity rate for DQA1∗ 05:
05 and DQA1∗ 03:01 compared to controls, but HLA-DQA1
was not included in our analysis. In addition, HLA-DQB1∗ 03:
01 homozygous individuals were of a significantly higher
frequency in red- or fair-haired patients. -ese grouping
standards were not analyzed within this study [19].
Upon comparison between HLA allele frequency and
clinical and histological parameters, no association between
HLA and ulceration, sentinel lymph node biopsy, and the type
of melanoma was observed, consistent with previous studies.
Lee et al. reported that HLA-DQB1∗ 03:01 was of a higher
frequency rate in subgroups with thicker melanomas and re-
gional metastasis [13]. In this study, the frequency of HLA-
DQB1∗ 03:01 was comparable betweenmelanoma and control
patients (17% vs. 17.9%, respectively). In contrast, HLA-
DQB1∗ 05:02 (6.5% vs. 2%, p � 0.001, Pc� 0.017, OR� 3.44)
showed an increased frequency in melanoma patients with
thicker Breslow. -ese differences may be explained by the
distinct ethnical origins of the studies.
Some limitations of this study should be noted. First,
HLA-DRB1∗ 16:01 and HLA-DQB1∗ 05:02 were not the
most frequent alleles. Second, the sample number will be
increased in future studies to provide more stable and re-
liable data. -e relationship between HLA class II allele
linkage disequilibrium and melanoma also requires as-
sessment in future studies.
5. Conclusion
In summary, HLA-DRB1∗ 16:01 and HLA-DQB1∗ 05:02
showed a positive association with melanoma. In addition,
both alleles were of a higher frequency in subgroups with
a higher Breslow thickness and relatively early age of di-
agnosis. Based on these results, we support the notion that
the HLA-DRB1∗ 16:01 and HLA-DQB1∗ 05:02 loci rep-
resent risk factors for melanoma development and
progression.
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